Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 2:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Pramipexole Clear all
Completed Phase 1Phase 2 Interventional

R(+)PPX High Dose Treatment of ALS

NCT00600873
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
R(+) pramipexole dihydrochloride monohydrate
Drug
Lead sponsor
Bennett, James P., Jr., M.D., Ph.D.
Individual
Eligibility
30 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 12, 2010 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 2 Interventional

Bipolar Study of Seroquel XR With Pramipexole Dihydrochloride

NCT00893841
View directory record Official record
Conditions
Bipolar Depression
Interventions
quetiapine (Seroquel) XR, placebo, pramipexole dihydrochloride
Drug
Lead sponsor
Dr. D McIntosh & Dr. K Kjernisted Clinical Research Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
San Diego, California • Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Feb 3, 2013 · Synced Sep 1, 2026, 2:52 PM EDT
Recruiting Phase 2 Interventional

Stratified Pharmacological Approaches for Regulating Circuit-Level Effects

NCT07022405
View directory record Official record
Conditions
Depression - Major Depressive Disorder
Interventions
Pramipexole Immediate Release
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 1, 2026, 2:52 PM EDT
Terminated Phase 2 Interventional Results available

Pramipexole ER vs. Placebo in Fibromyalgia

NCT00689052
View directory record Official record
Conditions
Fibromyalgia
Interventions
pramipexole ER, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2014 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 3 Interventional Results available

Polysomnography Study Of Pregabalin And Pramipexole Versus Placebo In Patients With Restless Legs Syndrome And Associated Sleep Disturbance

NCT00991276
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
pregabalin, placebo, pramipexole
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
41
States / cities
Jasper, Alabama • Phoenix, Arizona • Tucson, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2021 · Synced Sep 1, 2026, 2:52 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma

NCT05748600
View directory record Official record
Conditions
Eosinophilic Asthma, Asthma; Eosinophilic, Asthma Attack
Interventions
Dexpramipexole Dihydrochloride, Placebo
Drug
Lead sponsor
Areteia Therapeutics
Industry
Eligibility
12 Years to 99 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
146
States / cities
Chandler, Arizona • Peoria, Arizona • Surprise, Arizona + 123 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 1, 2026, 2:52 PM EDT
Withdrawn Phase 4 Interventional

Butrans for Treatment of Restless Legs Syndrome

NCT02138357
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
buprenorphine transdermal delivery system (BTDS), Placebo for BTDS patch
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
25 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 4 Interventional

SWITCH:Restless Legs Patients Switched to Ropinirole From Pramipexole

NCT00344994
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
pramipexole
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated May 12, 2011 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Dexpramipexole in ALS

NCT01281189
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Dexpramipexole, Placebo
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
942 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
43
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fresno, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2021 · Synced Sep 1, 2026, 2:52 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Treatment of Restless Legs Symptoms With Pramipexole to Improve the Outcomes of Protracted Opioid Withdrawal in OUD

NCT04759703
View directory record Official record
Conditions
Sleep Disorder, Restless Legs Syndrome, Opioid-use Disorder, Opioid Withdrawal
Interventions
Pramipexole, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts • Quincy, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 1, 2026, 2:52 PM EDT
Terminated Phase 3 Interventional Results available

Combined Treatment of Prolonged Exposure and Pramipexole for Posttraumatic Stress Disorder and Depression

NCT03765138
View directory record Official record
Conditions
PTSD, MDD
Interventions
PE/Pramipexole
Combination Product
Lead sponsor
Research Foundation for Mental Hygiene, Inc.
Other
Eligibility
18 Years to 60 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Sep 1, 2026, 2:52 PM EDT
Terminated Phase 3 Interventional

Phase III Long-Term Extension Study With Dexpramipexole

NCT06388889
View directory record Official record
Conditions
Eosinophilic Asthma
Interventions
Dexpramipexole Dihydrochloride
Drug
Lead sponsor
Areteia Therapeutics
Industry
Eligibility
18 Years to 99 Years
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
23
States / cities
Bakersfield, California • Northridge, California • Coral Gables, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 1, 2026, 2:52 PM EDT
Terminated Phase 3 Interventional

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)

NCT05813288
View directory record Official record
Conditions
Eosinophilic Asthma, Asthma; Eosinophilic, Asthma
Interventions
Dexpramipexole Dihydrochloride, Placebo
Drug
Lead sponsor
Areteia Therapeutics
Industry
Eligibility
12 Years to 99 Years
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
76
States / cities
Mobile, Alabama • Chandler, Arizona • Peoria, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Volunteers of the Bioavailability of Dexpramipexole Tablets and Food Effects

NCT01607034
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Dexpramipexole
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 2 Interventional

Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease

NCT00096720
View directory record Official record
Conditions
Parkinson Disease, Parkinsonian Syndrome
Interventions
levodopa, Mirapex (pramipexole), [123I]ß-CIT and SPECT imaging
Drug · Procedure
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
30 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
13
States / cities
Oxnard, California • Englewood, Colorado • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2010 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dexpramipexole and Warfarin Drug Drug Interaction (DDI) Study

NCT01597310
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Warfarin, Dexpramipexole
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Sep 1, 2026, 2:52 PM EDT
Terminated No phase listed Observational

The Long Term Impact of Initiating Pramipexole Versus Levodopa in Early Parkinson's Disease (CALM-PD Cohort Study)

NCT00804479
View directory record Official record
Conditions
Parkinson's Disease
Interventions
No intervention.
Other
Lead sponsor
University of Rochester
Other
Eligibility
Not listed
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 2 Interventional Results available

Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS)

NCT00647296
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Placebo, Dexpramipexole 50 mg/day, Dexpramipexole 150 mg/day, Dexpramipexole 300 mg/day
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
21 Years to 80 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
21
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Imaging Dopamine Release in Depression

NCT02033369
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Pramipexole
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 4 Interventional Results available

A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients

NCT00402233
View directory record Official record
Conditions
Parkinson Disease
Interventions
Pramipexole, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
31 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
39
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fountain Valley, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 4 Interventional Results available

Switching From Oral Dopamine Agonists to Rotigotine

NCT01976871
View directory record Official record
Conditions
Restless Legs Syndrome, Ekbom Syndrome, Willis-Ekbom Disease
Interventions
Rotigotine
Drug
Lead sponsor
John Winkelman, MD, PhD
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Sep 1, 2026, 2:52 PM EDT
Not listed Phase 2 Interventional

Pramipexole to Enhance Social Connections

NCT06269146
View directory record Official record
Conditions
Anxiety Disorders, Anxiety, Depression, Social Disconnection
Interventions
Pramipexole Pill, Placebo Pill
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 50 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
San Diego, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients

NCT00479401
View directory record Official record
Conditions
Early Parkinson Disease (Early PD)
Interventions
Pramipexol Extended Release, Pramipexol Immediate Release, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
30 Years and older
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
16
States / cities
Gilbert, Arizona • Sun City, Arizona • La Jolla, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2014 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 2 Interventional Results available

Safety Study of R(+)Pramipexole to Treat Early Alzheimer's Disease

NCT01388478
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
R-pramipexole
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
55 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Sep 1, 2026, 2:52 PM EDT